Pfizer Inc. reported first‑quarter 2026 results on May 5, 2026, posting total revenue of $14.45 billion and adjusted earnings per share of $0.75. The company beat consensus estimates of $13.84 billion in revenue and $0.72 in adjusted EPS, a revenue beat of $0.61 billion (≈4.4 %) and an EPS beat of $0.03 (≈4.2 %). The upside was driven by stronger demand for oncology and biosimilar products, a 7 % operational rise in non‑COVID sales, and disciplined cost management that reduced cost of sales by $1.1 billion and SG&A by $59 million.
COVID‑related revenue fell sharply, with Comirnaty sales down 59 % and Paxlovid sales down 63 % compared with the same quarter a year earlier, reflecting the waning demand for pandemic‑era products.
Adjusted operating income climbed 18 % to $4.29 billion, a gain largely attributable to the $1.1 billion reduction in cost of sales and the $59 million decrease in selling, general and administrative expenses, underscoring the effectiveness of Pfizer’s cost‑realignment program and its ability to generate margin expansion amid a shifting product mix.
Pfizer reaffirmed its full‑year 2026 guidance, maintaining a revenue range of $59.5‑$62.5 billion and adjusted EPS of $2.80‑$3.00. Management noted that the guidance incorporates a 1.6 % headwind from the Inflation Reduction Act Medicare Part D redesign and a 1.5 % decline in COVID product sales, yet remains confident in its post‑COVID growth trajectory. The outlook also reflects the expected impact of the Seagen acquisition and the Metsera obesity platform, both positioned to drive future revenue growth.
The results underscore Pfizer’s transition from a pandemic‑dependent business to a diversified biopharma model. Strong performance in oncology, bolstered by the Seagen acquisition, and growth in launched and acquired products such as Padcev and Abrysvo, offset the decline in legacy COVID products and support a margin‑expanding quarter. The company’s cost‑control initiatives and strategic acquisitions signal a clear path to sustainable long‑term growth, while the reaffirmed guidance highlights management’s cautious optimism amid headwinds from regulatory changes and competitive pressures.
Albert Bourla said, “We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer.” He added, “Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid‑stage results building meaningful momentum – and I'm particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.” He also noted, “We think this really changes dramatically the oncology presence of Pfizer and makes it one of a kind.” and “We aren't acquiring the golden eggs, we are buying the goose that lays the golden eggs.” CFO David Denton remarked, “Our first‑quarter results are attributable to our solid commercial performance globally as well as our ongoing focus on operational efficiency. This quarter, I'm particularly pleased with the 22 % year‑over‑year operational revenue growth from our launched and acquired products. Today, we are reaffirming our full‑year 2026 financial guidance.” He added, “I have a philosophy of not really adjusting in Q1.”
Investors responded positively to the earnings beat, noting the robust performance of non‑COVID products and the company’s disciplined cost management, while the unchanged guidance tempered enthusiasm, reflecting concerns about the impact of the Inflation Reduction Act and the continued decline in pandemic‑era sales.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.